BDTX (Black Diamond) Wutah bathi ing taun lumaku

Simbol resmi perusahaan blackdiamondtherapeutics.com (BDTX)

Black Diamond (BDTX) maintains high profitability by attracting top bioinformaticians through innovative software and RSUs. The 12-month earnings per share growth rate smooths out market noise, with the metric remaining around -281.20. Monopoly income within the rare mutations niche is secured by its scientific foundation, while drug production is optimized via an external network of certified CMO partners.

BDTX (Black Diamond Therapeutics) riwayat Wutah bathi ing taun lumaku saka 04.07.2022 nganti 15.11.2026

Rincian metrik komprehensif lan analitis Black Diamond (BDTX)

Produk mawa merek Black Diamond Therapeutics, Inc

Black Diamond (BDTX) maintains a strong position in precision oncology, where the efficiency of developing targeted inhibitors directly impacts capitalization. The year-over-year earnings per share dynamics measure net income growth rates, reflecting a real expansion of business margins, which is clearly visualized by the annual EPS variation in the GURU.Markets analytical interface to assess the issuer's fundamental stability.

Pesaing langsung